NervGen Pharma (NASDAQ:NGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of NervGen Pharma (NASDAQ:NGEN) have earned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $14.00.

Several brokerages have recently issued reports on NGEN. Leerink Partners began coverage on shares of NervGen Pharma in a research report on Monday, July 13th. They set an “outperform” rating and a $10.00 price target on the stock. HC Wainwright raised shares of NervGen Pharma to a “strong-buy” rating in a research note on Tuesday, April 28th. Wall Street Zen upgraded shares of NervGen Pharma from a “sell” rating to a “hold” rating in a report on Monday, July 20th. Weiss Ratings cut shares of NervGen Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Finally, TD Cowen started coverage on shares of NervGen Pharma in a research note on Thursday, June 11th. They issued a “buy” rating for the company.

NervGen Pharma Price Performance

Shares of NASDAQ NGEN opened at $1.72 on Friday. NervGen Pharma has a twelve month low of $1.58 and a twelve month high of $6.30. The company has a fifty day moving average price of $1.87. The firm has a market capitalization of $138.68 million and a PE ratio of -19.11.

NervGen Pharma (NASDAQ:NGEN) last posted its earnings results on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). As a group, analysts expect that NervGen Pharma will post -0.33 EPS for the current year.

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.